The entire optic nerve disorder treatment market has been sub-categorized into treatment type, indication, and end-user. current and future demand for optic nerve disorder treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
By Treatment Type
- Pharmacological Treatment
- Prostaglandin
- Beta Interferons
- Beta Blockers
- Alpha-adrenergic Agonist
- Carbonic Anhydrase Inhibitors
- Corticosteroids
- Combination Drugs
- Others
- Surgery
By Indication
- Glaucoma
- Optic Neuritis
- Optic Neuropathy
- Arteritic Ischemic Optic Neuropathy
- Non-arteritic Ischemic Optic Neuropathy
- Congenital Optic Atrophy
- Others
By End User
- Hospitals
- Ambulatory Surgery Centers
- Clinics
- Others
Sharp rise in the nerve disorders such as multiple sclerosis (MS), glaucoma and optic neuritis is driving the demand optic nerve disorder treatment. The National Eye Institute, total cases of glaucoma is projected to reach 6.3 million by 2050 in US alone. Rising aged population worldwide with higher prevalence of blinding in the elderly population created higher need for optic nerve disorder treatment market. Ongoing R&D programs in the key companies with increase in FDA approvals for the treatment of optic nerve disorders promotes growth of this market.
The major players in the optic nerve disorder treatment market include Santen Pharmaceutical Co., Ltd., Allergan plc., Novartis AG, Pfizer, Inc., Bausch Health Companies, Inc., Aerie Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bionure Farma, S.L. and Mallinckrodt Pharmaceuticals.
Source: https://www.valuemarketresearch.com/report/optic-nerve-disorders-treatment-market
Naira Shekhawat has been into Content Writing just after completing her Graduation in English Literature. Her love for words has won her many accolades in her respective jobs ever since. Naira covers business sections for VMR News. She is a traveller by heart and loves writing on food blogs as a freelancer.